Q2 2020 EPS Estimates for Natera Inc Cut by Analyst (NASDAQ:NTRA)

Q2 2020 EPS Estimates for Natera Inc Cut by Analyst (NASDAQ:NTRA)

Natera Inc (NASDAQ:NTRA) – Investment analysts at Piper Jaffray Companies cut their Q2 2020 earnings per share (EPS) estimates for shares of Natera in a research note issued on Sunday, June 9th. Piper Jaffray Companies analyst W. Quirk now forecasts that the medical research company will post earnings per share of ($0.44) for the quarter, down from their previous forecast of ($0.41). Piper Jaffray Companies has a “Overweight” rating and a $28.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Natera’s Q3 2020 earnings at ($0.42) EPS, Q4 2020 earnings at ($0.39) EPS and FY2020 earnings at ($1.73) EPS.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.05. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. The firm had revenue of $66.82 million during the quarter, compared to the consensus estimate of $66.40 million.

NTRA has been the subject of several other research reports. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Natera in a research report on Monday, March 11th. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Friday, March 8th. Finally, BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 20th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Natera has an average rating of “Buy” and an average price target of $28.25.

Shares of NTRA stock opened at $24.59 on Wednesday. The company has a quick ratio of 1.73, a current ratio of 1.85 and a debt-to-equity ratio of 20.88. Natera has a fifty-two week low of $11.08 and a fifty-two week high of $29.62. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -11.44 and a beta of 1.41.

Hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC grew its stake in shares of Natera by 6.0% in the first quarter. Parametric Portfolio Associates LLC now owns 12,331 shares of the medical research company’s stock worth $254,000 after acquiring an additional 700 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Natera by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock valued at $160,000 after acquiring an additional 717 shares during the period. Legal & General Group Plc lifted its holdings in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares during the period. California State Teachers Retirement System lifted its holdings in Natera by 1.8% in the first quarter. California State Teachers Retirement System now owns 51,722 shares of the medical research company’s stock valued at $1,067,000 after acquiring an additional 916 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. lifted its holdings in Natera by 10.5% in the first quarter. JGP Global Gestao de Recursos Ltda. now owns 13,518 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 1,280 shares during the period. 80.32% of the stock is currently owned by institutional investors.

In related news, CTO Jonathan Sheena sold 118,463 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $20.50, for a total value of $2,428,491.50. Following the sale, the chief technology officer now directly owns 355,621 shares of the company’s stock, valued at $7,290,230.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Matthew Rabinowitz sold 1,418 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $35,152.22. Following the completion of the sale, the chairman now directly owns 1,286,612 shares in the company, valued at $31,895,111.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 316,632 shares of company stock valued at $6,507,731. 9.29% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: What are some reasons analysts would give stocks a buy rating?

Earnings History and Estimates for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.




Natera Inc (NASDAQ:NTRA) – Investment analysts at Piper Jaffray Companies cut their Q2 2020 earnings per share (EPS) estimates for shares of Natera in a research note issued on Sunday, June 9th. Piper Jaffray Companies analyst W. Quirk now forecasts that the medical research company will post earnings per share of ($0.44) for the quarter, down from their previous forecast of ($0.41). Piper Jaffray Companies has a “Overweight” rating and a $28.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Natera’s Q3 2020 earnings at ($0.42) EPS, Q4 2020 earnings at ($0.39) EPS and FY2020 earnings at ($1.73) EPS.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.05. Natera had a negative return on equity of 699.31% and a negative net margin of 49.33%. The firm had revenue of $66.82 million during the quarter, compared to the consensus estimate of $66.40 million.

NTRA has been the subject of several other research reports. Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Natera in a research report on Monday, March 11th. Zacks Investment Research downgraded Natera from a “hold” rating to a “sell” rating in a report on Friday, March 8th. Finally, BidaskClub upgraded Natera from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 20th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Natera has an average rating of “Buy” and an average price target of $28.25.

Shares of NTRA stock opened at $24.59 on Wednesday. The company has a quick ratio of 1.73, a current ratio of 1.85 and a debt-to-equity ratio of 20.88. Natera has a fifty-two week low of $11.08 and a fifty-two week high of $29.62. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -11.44 and a beta of 1.41.

Hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC grew its stake in shares of Natera by 6.0% in the first quarter. Parametric Portfolio Associates LLC now owns 12,331 shares of the medical research company’s stock worth $254,000 after acquiring an additional 700 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in Natera by 6.7% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock valued at $160,000 after acquiring an additional 717 shares during the period. Legal & General Group Plc lifted its holdings in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares during the period. California State Teachers Retirement System lifted its holdings in Natera by 1.8% in the first quarter. California State Teachers Retirement System now owns 51,722 shares of the medical research company’s stock valued at $1,067,000 after acquiring an additional 916 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. lifted its holdings in Natera by 10.5% in the first quarter. JGP Global Gestao de Recursos Ltda. now owns 13,518 shares of the medical research company’s stock valued at $279,000 after acquiring an additional 1,280 shares during the period. 80.32% of the stock is currently owned by institutional investors.

In related news, CTO Jonathan Sheena sold 118,463 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $20.50, for a total value of $2,428,491.50. Following the sale, the chief technology officer now directly owns 355,621 shares of the company’s stock, valued at $7,290,230.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Matthew Rabinowitz sold 1,418 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $24.79, for a total value of $35,152.22. Following the completion of the sale, the chairman now directly owns 1,286,612 shares in the company, valued at $31,895,111.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 316,632 shares of company stock valued at $6,507,731. 9.29% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: What are some reasons analysts would give stocks a buy rating?

Earnings History and Estimates for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.